Herewith three items of recent pandemic news: More studies on mixing vaccine doses; the FDA extends Pfizer’s authorization to ages 12+; and acknowledgement from the CDC that this virus is airborne. Plus news briefs and a frippery. It is indeed … Continue reading →
Herewith three items of pandemic news you may have missed recently: Two more Russian vaccines; a primer on T-cell immunity; and fabulous results from a real-world study of vaccine effectiveness. Plus news briefs and two fripperies. 90% effective in the … Continue reading →
Three items of pandemic news you may have missed recently: Kids and Covid-19; enhanced lethality of the B.1.1.7 variant; and more on the pause in AstraZeneca shots as Europe investigates a rare condition. Plus news briefs and a frippery. AstraZeneca … Continue reading →
J&J confirmed reports that its large-scale clinical trial will begin in September, involving 60,000 subjects worldwide — twice the size of the Phase IIIs begun in July by Pfizer and Moderna. The study is not yet recruiting. Johnson & Johnson … Continue reading →
